The title of this paper is:
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
The first author is:
Bruce E. Sands M.D.
The paper was published in
'The New England Journal of Medicine' on the 25th of September 2024.
For those in a hurry,
here is a brief overview of the paper: Tulisokibart, a TL1A monoclonal antibody, was tested in a trial for patients with moderately to severely active ulcerative colitis, including a subgroup identified by a genetic test predicting a higher likelihood of response. The treatment significantly improved clinical remission rates compared to placebo, with a similar and generally mild-to-moderate adverse event profile. If you would like a little more detail, lets go thought the paper.
Lee
Jessica
Samantha
David
Our advanced AI system analyses medical journals and research papers to:
You can select from a wide range of medical specialties and topics to create a personalised content feed that delivers precisely what you're interested in.
Below is an example for gatroenterology and some of the categories available to select from. Your article feed can be more general or you can get as specific as you like. You choose.
Categories
Interests
Biomarkers in IBD
Capsule Endoscopy
Colonoscopy
CT Enterography
Differential Diagnosis
Endoscopy in IBD
Fecal Calprotectin
Histopathology in IBD
IBD Imaging
MRI Enterography
Colorectal Cancer in IBD
Crohns Disease Phenotypes
Extraintestinal Manifestations (EIMs)
Fistulizing Crohns Disease
IBD and Cancer Risk
IBD and Hepatobiliary Disease
IBD and Osteoporosis
IBD Remission
Primary Sclerosing Cholangitis (PSC)
Stricturing Crohns Disease
Our database is updated daily with the latest research from thousands of medical journals worldwide.
Save articles to your favourites for easy reference later. The system remembers which ones you've listened to.
Create custom playlists by topic or specialty that fits your learning style.
Your feed evolves based on your listening patterns and explicit preferences.